#42 – Nicole K. Paulk, CEO & Founder at Siren Biotechnology

Share This Post

In This Episode We Discuss: Gene Therapy Innovation

Join us on the latest episode! Our Guest: Nicole K. Paulk, CEO & Founder at Siren Biotechnology.

What you’ll get out of this episode:
  • Nicole Paulk’s early inspiration in gene therapy during her PhD at OHSU.
  • The transition from academia to entrepreneurship amid COVID-19.
  • Siren Biotechnology’s innovative approach with AAV immunogene therapy.
  • The challenges and successes in securing funding and navigating regulatory landscapes.
  • The exciting transition of Siren Biotechnology from preclinical to clinical trials.

Watch

Listen

Read More on Gene Therapy Innovation

Early Inspiration in Gene Therapy

Nicole Paulk’s journey into the world of gene therapy began during her PhD at Oregon Health & Science University (OHSU) in Portland. Despite the challenges of an unpopular field due to halted FDA trials, Nicole was captivated by the elegance of using viruses to replace missing or defective genes. This passion drove her to contribute significantly to the field, publishing six papers in just four years.

Transition from Academia to Entrepreneurship

The shift from academia to entrepreneurship was not common for professors, especially during the peak of COVID-19. Nicole’s frustration with the inability to access her lab at UCSF pushed her to take a bold step. Despite the pandemic’s challenges, including severe restrictions and supply chain issues, Nicole successfully launched Siren Biotechnology, moving her team and equipment to an incubator across the street.

Siren Biotechnology’s Innovative Approach

Siren Biotechnology stands out by pioneering AAV immunogene therapy, a groundbreaking approach that expands the traditional use of gene therapy. Unlike conventional methods targeting rare genetic disorders, Siren’s universal payload project aims to create therapies applicable across multiple diseases. This innovation has the potential to address cost and scalability issues, making gene therapy more accessible for common disorders like cancer, diabetes, and heart failure.

Securing Funding and Navigating Challenges

Nicole’s expertise in grant writing proved invaluable as Siren Biotechnology navigated the complex funding landscape. Initially, securing VC money was straightforward, but as the market adjusted, non-dilutive grant money became crucial. Nicole’s ability to harness this skill set enabled Siren to continue its research and development, ensuring the company’s growth despite market fluctuations.

Transition to Clinical Trials

Siren Biotechnology is at a pivotal moment, transitioning from a preclinical to a clinical company. This involves producing clinical-grade viral vectors, submitting FDA documentation, and conducting IND-enabling animal experiments. The excitement of moving towards dosing human subjects is palpable, marking a significant milestone in the company’s journey.

Conclusion

Nicole Paulk’s dedication and innovative approach are driving Siren Biotechnology to new heights in gene therapy. As the company transitions to clinical trials, the potential for transformative treatments becomes increasingly tangible.

WORD FROM OUR SPONSORS:

Our sponsor for this episode are Sage Growth Partners.

Sage Growth Partners Thumbnail for biopharma use on Slice of Healthcare's website.

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners

To learn more about our guest and their innovative addiction treatments:

Guest LinkedInCompany LinkedInWebsite


Also, be sure to follow Slice of Healthcare on our social channels:

– Website  – LinkedIn – Twitter – YouTube – Newsletter

More To Explore

Total
0
Share